耶氏肺孢子菌肺炎临床特点及KL-6诊断价值

中国真菌学杂志　 2021, Vol. 16 　Issue (1): 19-23.

耶氏肺孢子菌肺炎临床特点及KL-6诊断价值

陈艳慧, 钟桥石, 杭亚平, 方雪瑶, 肖艳萍, 曹星卫, 朱鸿英, 罗红, 胡龙华

南昌大学第二附属医院检验科, 江西医学检验重点实验室, 南昌 330006

收稿日期:2020-03-06 发布日期:2021-02-25
通讯作者: 胡龙华,E-mail:longhuahu@163.com E-mail:longhuahu@163.com
作者简介:陈艳慧,女(汉族),硕士,初级检验师.E-mail:cyhxl68@foxmail.corn
基金资助:
江西省卫生健康委科技计划（20204336）；江西省中医药科技计划（2019A264）

Clinical characteristics and diagnostic value of KL-6 in Pneumocystis jirovecii pneumonia

CHEN Yanhui, ZHONG Qiaoshi, HANG Yaping, FANG Xueyao, XIAO Yanping, CAO Xingwei, ZHU Hongying, LUO Hong, HU Longhua

Clinical laboratory of The Second Affiliated Hospital of Nanchang University, Jiangxi Province Key Laboratory of Laboratory Medincine, Nanchang 330006, China

Received:2020-03-06 Published:2021-02-25

摘要/Abstract

摘要： 目的分析本地区耶氏孢子菌肺炎（Pneumocystis jirovecii pneumonia，PJP）患者的流行趋势、临床特征、血清学标志物，为PJP患者的早预防、早诊断提供理论依据。方法回顾性分析江西省3所综合性医院2016年1月至2019年12月诊断为PJP的49例住院患者，收集患者临床资料，包括基本信息、危险因素、临床表现、实验室结果、影像学报告、预后等。结果 49例PJP患者绝大多数HIV阴性（89.8%），且以中年男性为主。AIDS、肾脏疾病（47.7%）和结缔组织疾病（29.6%）为PJP患者主要危险因素，临床表现以干咳（83.7%）、白色黏痰，发热（79.6%）为主，其次为呼吸困难。PJP患者以低剂量/短时间（<3个月）使用糖皮质激素或免疫抑制剂为特征。85%以上PJP患者实验室指标超过参考范围的有中性粒细胞百分比、C反应蛋白、氧分压、乳酸脱氢酶和涎液化糖链抗原-6（KL-6）。结论 HIV阴性患者感染PJ逐渐增多，肾脏疾病和结缔组织疾病是其主要危险因素，LDH、BG和KL-6可作为PJP患者的重要辅助检查。

关键词: 耶氏肺孢子菌, 肺炎, HIV, 涎液化糖链抗原-6

Abstract: Objective To analyze the prevalence, clinical characteristics and serological markers of pneumocystis jirovecii pneumonia (PJP) patients in this region, and to provide theoretical basis for early prevention and early diagnosis of PJP. Methods A retrospective study of 49 hospitalized patients with PJP from January 2016 to December 2019 in three general hospitals in jiangxi province was conducted. Information was collected regarding patient demographics, clinical manifestations, risk factors, laboratory analyses, radiological images, and treatment outcomes. Results The vast majority of PJP were HIV negative (89.8%) and were predominantly found in middle-aged males. HIV/AIDS, kidney disease (47.7%) and connective tissue disease (29.6%) were the main risk factors for PJP. The main clinical manifestations were dry cough (83.7%), white phlegm, and fever (79.6%), followed by dyspnea. The PJP patients had received glucocorticoid, immunosuppressant and/or chemotherapy in a low dose or for a short duration (<3 months). Biochemical investigations of Neu%, CRP, PO₂, LDH, and KL-6 showed that over 85% of cases exceeded the reference range of indicators. Conclusion HIV-negative patients infected with PJ were increasing, and renal disease and connective tissue disease might be main risk factors. LDH, BG and kl-6 might be used as important auxiliary examinations for PJP patients.

Key words: Pneumocystis jirovecii, pneumonia, HIV, KL-6

中图分类号:

R563.1

陈艳慧, 钟桥石, 杭亚平, 方雪瑶, 肖艳萍, 曹星卫, 朱鸿英, 罗红, 胡龙华. 耶氏肺孢子菌肺炎临床特点及KL-6诊断价值[J]. 中国真菌学杂志, 2021, 16(1): 19-23.

CHEN Yanhui, ZHONG Qiaoshi, HANG Yaping, FANG Xueyao, XIAO Yanping, CAO Xingwei, ZHU Hongying, LUO Hong, HU Longhua. Clinical characteristics and diagnostic value of KL-6 in Pneumocystis jirovecii pneumonia[J]. Chinese Journal of Mycology, 2021, 16(1): 19-23.

参考文献

[1] Eddens T, Kolls JK. Pathological and protective immunity to Pneumocystis infection[J]. Semin Immunopathol, 2015,37(2):153-162.
[2] Huang Y, Yang J, Lee N, et al. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients:a review[J]. Expert Rev Anti Infect Ther, 2017,15(9):873-892.
[3] Shibata S, Kikuchi T. Pneumocystis pneumonia in HIV-1-infected patients.[J]. Respir Investig, 2019,57(3):213-219.
[4] Calderón EJ, Gutiérrez-Rivero S, Durand-Joly I, et al. Pneumocystis infection in humans:diagnosis and treatment[J]. Expert Rev Anti Infective Ther, 2010,8(6):683-701.
[5] Roux A, Canet E, Valade S, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France[J]. Emerg Infect Dis, 2014,20(9):1490-1497.
[6] 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 中华临床感染病杂志, 2018,11(6):411-432.
[7] Huang L, Cattamanchi A, Davis JL, et al. HIV-associated Pneumocystis pneumonia[J]. Proc Am Thorac Soc, 2011,8(3):294-300.
[8] Blaas S. Pneumocystis jirovecii pneumonia in patients with autoimmune diseases[J]. Z Rheumatol, 2017,76(9):761-766.
[9] White PL, Backx M, Barnes RA. Diagnosis and management of Pneumocystis jirovecii infection[J]. Expert Rev Anti Infect Ther, 2017,15(5):435-447.
[10] Turner D, Schwarz Y, Yust I. Induced sputum for diagnosing Pneumocystis carinii pneumonia in HIV patients:new data, new issues[J]. Eur Respir J, 2003,21(2):204-208.
[11] Guo F, Chen Y, Yang SL, et al. Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients:a retrospective study of two centers in China[J]. Plos One, 2014,9(7):e101943.
[12] Roblot F, Godet C, Moal GL, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients[J]. Eur J Clin Microbiol Infect Dis, 2002,21(7):523-531.
[13] CDC, IDSO. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients[J]. Cytotherapy, 2001,3(1):41-54.
[14] Kaplan JE, Benson C, Holmes K, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents.[J]. MMWR Recomm Rep, 2009,58(RR-4):1-207.
[15] Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia:diagnostic and prognostic significance[J]. Am Rev Respir Dis, 1988,137(4):796-800
[16] 吴海涵, 梁林, 于农, 等. 血清乳酸脱氢酶在耶氏肺孢子虫肺炎诊断、治疗及预后评估中的价值[J]. 检验医学与临床, 2014(1):111-112.
[17] Li WJ, Guo YL, Liu TJ, et al. Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan:a bivariate meta-analysis and systematic review.[J]. J Thorac Dis, 2015,7(12):2214.
[18] Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization:a prospective study[J]. BMC Infec Dis, 2009,9(1):47-52.
[19] Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia[J]. Chest, 2007,131(4):1173-1180.